HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Guest Access | Sign In via User Name/Password

This Article Full Text Free Full Text (PDF) Free Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to My Personal Article Archive Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (13) Citing Articles via Google Scholar Google Scholar Articles by Mahler, D. A. Search for Related Content PubMed PubMed Citation Articles by Mahler, D. A.

How Should Health-Related Quality of Life Be Assessed in Patients With COPD?^*

^* From the Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Correspondence to: Donald A. Mahler, MD, FCCP, Dartmouth Medical School, Section of Pulmonary and Critical Care Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH 03756-0001; e-mail: Donald.a.mahler{at}hitchcock.org

The traditional approach of caring for patients with chronic respiratory disease has been to rely on pulmonary function tests to quantify the severity and to assess response to therapy. However, patients with respiratory conditions seek medical attention because of symptoms, particularly dyspnea, and impaired ability to function, which clearly impact on an individual’s health-related quality of life (HRQOL). Accordingly, instruments have been developed to provide a standardized method to measure health status and levels of impairment. One of the major reasons for measuring HRQOL is to detect how much HRQOL has changed in response to therapy (an evaluative instrument). A minimum clinically significant change has been established for some HRQOL instruments in order to indicate the relative value of any measured change and to guide the interpretation as to whether the change is "clinically meaningful." Selected studies using disease-specific instruments have demonstrated that ß₂-agonist, anticholinergic, and theophylline medications can improve HRQOL, as compared with placebo therapy.

Key Words: bronchodilator therapy • disease-specific instrument • dyspnea • generic health measure • minimum clinically significant change

This article has been cited by other articles:

				A. D. Lopez, K. Shibuya, C. Rao, C. D. Mathers, A. L. Hansell, L. S. Held, V. Schmid, and S. Buist Chronic obstructive pulmonary disease: current burden and future projections Eur. Respir. J., February 1, 2006; 27(2): 397 - 412. [Full Text] [PDF]

				M. D. Sprenkle, D. E. Niewoehner, D. B. Nelson, and K. L. Nichol The Veterans Short Form 36 Questionnaire Is Predictive of Mortality and Health-Care Utilization in a Population of Veterans With a Self-Reported Diagnosis of Asthma or COPD Chest, July 1, 2004; 126(1): 81 - 89. [Abstract] [Full Text] [PDF]

				R. L. ZuWallack, D. A. Mahler, D. Reilly, N. Church, A. Emmett, K. Rickard, and K. Knobil Salmeterol Plus Theophylline Combination Therapy in the Treatment of COPD Chest, June 1, 2001; 119(6): 1661 - 1670. [Abstract] [Full Text] [PDF]

				P. M. A. Calverley The Future for Tiotropium Chest, February 1, 2000; 117(2_suppl): 67S - 69S. [Abstract] [Full Text] [PDF]